{"preliminary_commentary":{"by_channel":{"youtube":14,"podcast":8,"x_thread":5,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05197192\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"CLL16","nct_id":"NCT05197192","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cll16-nct05197192. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Acalabrutinib plus Venetoclax plus Obinutuzumab plus (GAVe)","label":"GAVe-Arm","type":"EXPERIMENTAL"},{"description":"Obinutuzumab plus Venetoclax (GVe)","label":"GVe-Arm","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2028-05","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia"],"enrollment":{"count":202,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Obinutuzumab","otherNames":["Gazyva","Gazyvaro"],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Venclexta","Venclyxto"],"type":"DRUG"},{"name":"Acalabrutinib","otherNames":["Calquence"],"type":"DRUG"}],"last_update":"2026-08-20","lead_sponsor":"German CLL Study Group","official_title":"A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk Chronic Lymphocytic Leukemia (CLL)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"50 months after FPI"}],"references":[],"start_date":{"date":"2022-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL","url":"https://clinicaltrials.gov/study/NCT05197192"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cll16-nct05197192"}